Express Pharma Pulse

India's No.1 Weekly For The Pharmaceutical Industry

About us || Feedback|| Advertising || Subscribe || Archives / Search

Issue dated - 21th Oct. 2004

Latest News

[an error occurred while processing this directive]

News Archives >>

Gates Foundation funding likely for Strand Genomics AIDS vaccine

Cipla makes fresh biotech investment; Wockhardt to fortify presence

Rofecoxib makers to fall back on alternatives

Samsung launches new version of HPMCP in India

INSIDE PHARMA

TECHNOLOGY TRENDZ

HAPPENINGS

PRODUCTS

Pharma Research
(Adobe PDF file)

IN THE NEWS	EDIT
Ranbaxy discontinues rofecoxib Soham Organics to expand its vitamin E facility	Editorial Cox-2 Acrobatics Edit Article Shock and pain after rofecoxib
OPED	BIOTECH
Regulatory affairs: An overview Presently, the strategy is to concentrate on drugs that can be marketed globally and offer some advantage over existing therapies, say Ravinder Reddy B and Suresh N	Accurate genetic determination in research
CORPORATE	TECHNOLOGY TRENDZ
Alkem to expand global business through CRO route Ranbaxy recasts China operations Glaxo plans clinical trials of malaria vaccine in India Indoco files draft prospectus for IPO Drager Medical drags government to court Ranbaxy reports 3.3 per cent de-growth in sales	Effective supply chain management Advances in anti-counterfeiting technologies
MARKET PLACE	HAPPENINGS
ADHD: An emerging market in India ADHD is a huge market which is untapped due to low awareness among parents and doctor. Pharmaceutical companies should see this as an opportunity, say R K Srivastava and Shailesh Shinde	Pharma Summit calls for policy reforms, networking for growth NIPER to hold training programme Narayana Hrudayalaya sets up bone marrow centre SIESCOMS holds Pharma Vision 2004 Co-opetition, networking key to pharma success: Industry WB govt to set up a biotech park, seeks private participation
CONVERSATION	PRODUCTS
‘IP is going to be a way of life’ A K Jain, executive director of the Rs 600 - crore Ipca Labs which is in the process of expanding its formulations capacity, in a tete-a-tete with Megha Lodha speaks on how soon it would be a part of the Rs 1,000 crore turnover segment.	Products

<Top of page>

© Copyright 2001: Indian Express Newspapers (Bombay) Limited (Mumbai, India). All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of the Indian Express Newspapers (Bombay) Limited. Site managed by BPD.